



The Manager  
Company Announcements  
Australian Stock Exchange  
4<sup>th</sup> Floor  
20 Bridge Street  
SYDNEY NSW 2000

4 April 2008

**RHT: Resonance Health gains Ethics Approval for Patient Outcome Study**

Resonance Health has received Ethics Committee approval for a study looking at *The effect of access to non-invasive liver iron concentration measurements on patients at risk of iron overload from multiple blood transfusions.*

The results of this study will form a key aspect of reimbursement submissions demonstrating the clinical benefits of the FerriScan<sup>®</sup> test to measure liver iron levels. Once reimbursed, the FerriScan<sup>®</sup> test will be accessible to many more patients, significantly improving the management of their disease.

This retrospective study will be concluded in April 2008 followed by the immediate submission for medical reimbursement for FerriScan<sup>®</sup> in Australia.

Clinician support for the MRI based FerriScan<sup>®</sup> test is high. Recently updated 'Guidelines for the Clinical Management of Thalassaemia' published by the Thalassaemia International Foundation recommends the use of FerriScan<sup>®</sup> to determine liver iron concentration which is now regarded as the reference standard for estimating body iron stores.

Untreated transfusional iron overload in thalassaemia major and sickle cell anaemia can be fatal. Assessing iron overload as accurately as possible is a key aspect of the clinical management of these patients.

Resonance Health's second reimbursement submission will target the UK market with over 7,000 patients in the UK at risk of transfusional iron overload.

Further information about Resonance Health and FerriScan<sup>®</sup> can be obtained from the web site: [www.resonancehealth.com](http://www.resonancehealth.com) or by sending an email to [info@ferriscan.com](mailto:info@ferriscan.com).

By Order of the Board

Resonance Health Limited